Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Phase 3
496
about 3.1 years
18+
Female only
103 sites in AL, AR, AZ +36
About this study
Researchers are testing a treatment called ubrogepant for menstrual migraine. The trial is testing how safe and effective ubrogepant is in treating menstrual migraine. Participants will take either ubrogepant or a placebo daily for 16 weeks, then may continue with ubrogepant for another 52 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo for Ubrogepant
- 2.Take Ubrogepant
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ubrogepant
oral (Oral Tablet)
Primary: Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period, Number of Participants With Adverse Events (AEs)
Secondary: Change From Baseline in Acute Medication Use Days During the Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period, Change From Baseline in Number of Headache Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period, Change From Baseline in Number of Migraine Days With Moderate or Severe Headache During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period, Change From Baseline in Number of Moderate or Severe Headache Days During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period
Neurology